Replies to post #330 on Novocure Ltd (NVCR)

[KIPK]

And the "NoCure, Not Good Enough Therapy Concept" gets more Reveals imo!!

[dstock07734]

Still have hope? If patients just take at minimum three shots of DCVax-L, they have very high probability cancer free, like what happened to Alice and Dan.



Will they wear something like this for over 18 hours a day? All the investors just need common sense to know the answer.




Dendritic cells after be activated and maturated by poly-iclc have maximum seven days life after migrating to lymph nodes. Three doses will be administered within 28 days. After 35 days, all the primed dendritic cells loaded tumor antigen are gone. Yet the anti-tumor response continues. How is that? Dr. Bosch said the following.

It presents peptides from both known GBM-associated tumor antigens, and tumor antigens which have not been reported in GBM before. And the presentation of these peptides, not only through class 1, remember important for cytotoxic T cells, but also through Class 2, to CD4 T cells, suggests that we also get T-cell memory responses in vivo. Something of course, that we believe is incredibly important in a chronic disease like GBM, where you can't just eradicate it at once. You needed ongoing response that continues to hammer away at the tumor. You need to set up that battle in the brain, where the immune system can continue to eradicate tumor cells, because they will continue to replicate otherwise. So this immune memory is actually critical for the, for the potential success.

Is it coincident that the C-suite of NVCR has been dumping their share ever since the first paper of p3 DCVax-L clinical trial were published in May 2018? The answer is no.

Six hundred patients already received DCVax-L, among which at least two hundreds were through the special program. It is just because of many patients that Professor Ashkan treated with DCVax-L that gave him the confidence that three doses of DCVax-L is enough to prime the immune system. So what are you waiting for?

Joels frozen tumour was only big enough to make 4 vaccines. Some of his tumour had already been sent to Heidelberg for analysis as part of the ipilimumab clinical trial he was part of. So they could only make 4 although 5 were given in the clinical trial for DCVax. Prof Ashkan said that 3 is enough to reprogram the immune system and the other doses are maintenance doses. This treatment is really expensive and we have had to crowdfund for it as you know. It’s probably cost around £190000. We did explore the German option with IOZK but decided against it for various reasons.